ALT vs LLY
ALT: Altimmune is a clinical-stage biopharmaceutical company developing pemvidutide, a dual GLP-1/glucagon agonist, to treat serious liver and metabolic disorders. LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies.
Side-by-side fundamentals
| Metric | ALT | LLY | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $2.60 | $1,169.60 | |
| Market cap | $506M | $1.10T | |
| P/E as of 2026-10-08 | n/a | 39.25 | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | n/a | 0.80 | |
| Net margin FY2025, SEC XBRL | -214861.0% | +31.7% | LLY higher |
| Operating margin FY2025, SEC XBRL | -230461.0% | n/a | |
| ROE FY2025, SEC XBRL | -39.2% | +77.8% | LLY higher |
| ROA FY2025, SEC XBRL | -31.5% | +18.4% | LLY higher |
| Debt / equity as of 2026-09-03 | 0.12 | 1.62 | ALT lower |
| Revenue growth (YoY) as of 2026-09-03 | +80.0% | +49.6% | ALT higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +31.7% | |
| Dividend yield as of 2026-09-03 | n/a | +0.6% | |
| Dividend streak (yrs) SEC XBRL | n/a | 10 | |
| Beta as of 2026-09-03 | 1.55 | 0.55 | |
| 1-year return as of 2026-10-08 close | -33.8% | +38.3% | LLY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.